NCT05030506View on ClinicalTrials.gov

A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

October 21, 2026

Study Completion Date

October 21, 2026

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Belzutifan

40 mg tablet administered orally at a dose of 120 mg

BIOLOGICAL

Pembrolizumab

25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg

DRUG

Lenvatinib

10 mg capsule administered orally at a dose of 20 mg

Trial Locations (5)

100142

Beijing Cancer hospital-Digestive Oncology ( Site 0001), Beijing

210000

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S, Nanjing

300060

Tianjin Medical University Cancer Institute and Hospital ( Site 0003), Tianjin

310052

The Second Affiliated hospital of Zhejiang University school of medicine-Urology ( Site 0007), Hangzhou

510060

SUN YAT-SEN UNIVERSITY CANCER CENTRE-Urology Surgery Department ( Site 0005), Guangzhou

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY